Horne, G. A. , Kinstrie, R. and Copland, M. (2015) Novel drug therapies in myelois leukemia: a patent review. Pharmaceutical Patent Analyst, 4(3), pp. 187-205. (doi: 10.4155/ppa.15.3) (PMID:26030080)
|
Text
106617.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Both acute myeloid leukemia and chronic myeloid leukemia are thought to arise from a subpopulation of primitive cells, termed leukemic stem cells that share properties with somatic stem cells. Leukemic stem cells are capable of continued self-renewal, and are resistant to conventional chemotherapy and are considered to be responsible for disease relapse. In recent years, improved understanding of the underlying mechanisms of myeloid leukemia biology has led to the development of novel and targeted therapies. This review focuses on clinically relevant patent applications and their relevance within the known literature in two areas of prevailing therapeutic interest, namely monoclonal antibody therapy and small molecule inhibitors in disease-relevant signaling pathways.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Horne, Dr Gillian and Kinstrie, Dr Ross and Copland, Professor Mhairi |
Authors: | Horne, G. A., Kinstrie, R., and Copland, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Pharmaceutical Patent Analyst |
Publisher: | Future Science Ltd. |
ISSN: | 2046-8954 |
ISSN (Online): | 2046-8962 |
Copyright Holders: | Copyright © 2015 The Authors |
First Published: | First published in Pharmaceutical Patent Analyst 4(3):187-205 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record